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ABSTRACT 41 
Physical activity is known to prevent cancer occurrence and to decrease the risk of breast cancer. At 42 
diagnosis of breast cancer, fewer than half of the patients reach the international recommendation for 43 
physical activity. However, breast cancer patients, and particularly HER2+ breast cancer patients, are 44 
exposed to treatment-induced cardiotoxicity because of a side effect of two molecules used in standard 45 
therapy to treat these tumors: anthracycline and trastuzumab.  Cardiotoxicity can sometimes lead to 46 
the treatment being discontinued and even to the development of cardiovascular diseases. Exercise is 47 
known to protect the cardiovascular system in the healthy population. Consequently, being physically 48 
active during treatment appears as a way to prevent the negative impact of cancer treatment on the 49 
heart in this population. In particular, aerobic exercising could provide a protective effect against 50 
treatment-induced cardiotoxicity. 51 
A supervised physical activity program seems to be the best way for breast cancer patients to be active 52 
during their period of treatment. However, there is very little information available to patients, and in 53 
particular a lack of guidelines, on exercising. Interventional trials that have been conducted on this 54 
topic are very heterogeneous and no standard recommendations have been made available for cancer 55 
patients thus far. An effective physical activity program needs to take each patient’s barriers and 56 
motivations into account in order to encourage the practice of physical activity throughout treatment. 57 
To ensure the success of the program, it is essential to facilitate adherence and especially to maintain 58 
motivation. Further studies are needed to determine what practice guidelines oncologists should give 59 
their patients. 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
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INTRODUCTION  68 
Physical inactivity is the fourth mortality risk worldwide [1]. Regardless of the level of physical 69 
activity, reducing sedentary time decreases mortality, and also the risk of developing cardiovascular 70 
diseases, type 2 diabetes, obesity and certain cancers [2]. In 2010, the World Health Organization 71 
(WHO) issued international physical activity recommendations for the healthy population, by age 72 
group [3]. Over the following years, these recommendations were extended to breast cancer patients 73 
through different frameworks and by different authorities, for example, the Plan Cancer in France [4] 74 
and the American Cancer Society [5,6].  75 
The link between high body mass index (BMI) at breast cancer diagnosis and poor prognosis has been 76 
well established, and highlights the importance of being physically active [7,8]. Physical activity  from  77 
diagnosis has become a routine recommendation in breast cancer treatment, especially because of its 78 
many benefits on quality-of-life [9,10]. Physical activity also improves survival rates. Indeed, a meta-79 
analysis has shown that being active after diagnosis is linked to a 34% reduction in breast cancer 80 
deaths, a 41 % reduction in deaths from all causes and a 24 % reduction in disease recurrence [11]. 81 
Another meta-analysis evaluating 5- and 10-year survival rates showed that the higher the level of 82 
physical activity, the better were the survival rates [12]. Indeed, the 5-year survival rate was 97 % for 83 
patients who engaged in 3 to 9 or more metabolic equivalent task (MET) hours per week, and 93 % for 84 
those who engaged in fewer than 3 MET-h/weeks. The 10-year survival rate of patients who engaged 85 
in 9 or more MET-h/week was 92 %, whereas for patients engaging in 3 to 8.9 MET-h/week it was 89 86 
%, and 86 % for those who practiced for fewer than 3 MET-h/week. However, at diagnosis, the 87 
majority of patients are insufficiently active [13–15] and maintaining an adequate level of physical 88 
activity during treatment can be difficult on account of the numerous barriers encountered by patients. 89 
The most frequent barriers identified over the last decades are treatment side effects and the 90 
management of everyday routine activities. In addition to improving the outcomes of cancer, physical 91 
activity could limit some of the toxicity of anticancer treatments. There is strong evidence that meeting 92 
the international physical activity recommendation (i.e. 150 to 300 minutes of moderate-intensity or 93 
75 to 150 minutes of vigorous-intensity aerobic activity on a weekly basis) reduces the incidence and 94 
recurrence of cardiometabolic disease [16,17]. It can thus be hypothesized that patients who develop 95 
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treatment-induced cardiotoxicity could draw benefit from a physical activity intervention. 96 
In order to promote physical activity during treatment, interventional programs are offered to patients. 97 
Since 2010, the literature on this topic has been developing, and the number of trials involving 98 
physical activity interventions has multiplied. Nevertheless, the question arises as to what is the 99 
optimal program, particularly in terms of duration, type of exercise or intensity. 100 
The aim of this review was to explore treatment-induced cardiotoxicity and identify the interest, 101 
barriers and facilitators of physical activity practice during treatment in order to mitigate cardiac 102 
dysfunction.  103 
 104 
I. BREAST CANCER AND CARDIOTOXICITY 105 
1. Anthracycline-induced cardiotoxicity 106 
Anthracyclines belong to the standard chemotherapy treatment for early breast cancer. Nevertheless, 107 
one limitation of this treatment is that it can cause cumulative, dose-dependent cardiac damage, mainly 108 
cardiomyopathy and heart failure [18,19]. 109 
Patients treated with anthracycline-based chemotherapy are five times more at risk of developing  110 
cardiotoxicity than those treated without anthracycline [20]. Some meta-analyses have also shown that 111 
the risk of severe cardiotoxicity is higher in patients under anthracycline-based chemotherapy than 112 
among those treated with taxanes without anthracycline [21,22]. Cardiotoxicity is defined by a left 113 
ventricular ejection fraction (LVEF) < 50 % or a decrease of 10 % in the LVEF compared to baseline 114 
[23–26]. It is the first cause of heart failure among women and is responsible for 15-20 % of cases of 115 
treatment discontinuation [27]. 116 
Two main hypotheses have been put forward to explain the potential mechanisms implicated in 117 
anthracycline-induced cardiotoxicity. Some authors have suggested that the reactive oxygen species 118 
(ROS) generated by anthracycline treatment cause damage to the DNA and changes in protein and 119 
lipid levels, ultimately leading to cardiomyocyte death [28–30]. It has also been shown that 120 
doxorubicin-induced cardiotoxicity is linked to the activation of p53 and the apoptotic pathway, 121 
leading to a loss of myocardia mass, which contributes to cardiotoxicity [31]. 122 
 123 
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2. Trastuzumab-induced cardiotoxicity  124 
Approximately 20 % of breast cancer patients overexpress the human epidermal growth factor receptor 125 
2 (HER2) [32]. This characteristic of the tumour has been associated with poorer disease-free and 126 
overall survival [32,33]. One of the standard treatments for this specific cancer is a targeted therapy, 127 
trastuzumab (Herceptin
®
), which can be administered alone [23,34] or in combination with 128 
chemotherapy [35,36]. Trastuzumab is a recombinant humanized monoclonal anti-body that binds 129 
selectively to subdomain IV of the extracellular ErbB2 domain, which downregulates HER2 130 
expression [37]. Adjuvant treatment with trastuzumab reduces by half the rate of recurrence and by 131 
one third the mortality rate [38].  132 
It is estimated that 1 % to 4 % of patients treated with trastuzumab develop heart failure [39,40] and 133 
nearly 10 % have asymptomatic LVEF reduction [35,41]. The cumulate incidence rate for major 134 
cardiac events has been estimated at 6.6 % for sequential therapy (anthracycline and trastuzumab) and 135 
5.1 % for trastuzumab alone [42]. A meta-analysis has shown that patients treated with trastuzumab 136 
were about five times more at risk  of developing congestive heart failure in early breast cancer 137 
compared to patients not treated with this targeted therapy [43]. Nevertheless, if trastuzumab is 138 
discontinued at the time of the first cardiac symptoms , the damage can be reversible [44]. 139 
It can be hypothesized that trastuzumab-induced cardiotoxicity is linked to  antibody-dependent 140 
cellular cytotoxicity (ADCC), leading to an immune-mediated destruction of cardiomyocytes or to a 141 
disruption of HER2 signalling, which is essential for myocardial contractility, see for example [44,45]. 142 
It is also important to note that HER2, the target of trastuzumab, is expressed in adult cardiomyocytes 143 
and is implicated in cardiomyocyte development [45–49]. When trastuzumab blocks HER2 signalling, 144 
it prevents the repair mechanisms in cardiomyocytes [50].  145 
 146 
3. Cardiotoxicity associated with anthracyclines and trastuzumab treatment 147 
When trastuzumab and anthracycline-based chemotherapy are associated, the incidence of 148 
cardiotoxicity is 27 % against 13 % when trastuzumab is associated with paclitaxel [51]. More 149 
generally, the risk of cardiac failure is higher when trastuzumab is administered after anthracycline-150 
based chemotherapy than after non-anthracycline chemotherapy [22]. Patients treated with 151 
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trastuzumab and chemotherapy are twice as likely to develop heart failure or LVEF decrease [52].  152 
Cardiotoxicity can occur acutely but it can also lead to cardiovascular disease development in the long 153 
term. A retrospective study compared the incidence of cardiotoxicity in the five years following 154 
treatment associating anthracycline and trastuzumab or anthracycline alone. Among the 29.6 % of the 155 
patients treated with anthracyclines alone, cardiotoxicity at five years involved 4.3 %, while for the 3.5 156 
% of population who received an association of the two drugs, the proportion was 20.1 %, more than 157 
4.5 times greater [53]. 158 
Today, new targeted anti-HER2 therapies are available, such as pertuzumab, trastuzumab emtansine 159 
(T-DM1), lapatinib, neratinib and afatinib, but they do not have an indication for early breast cancer. 160 
A study was conducted to determine the cardiac tolerance of pertuzumab. The TRYPHAENA study 161 
assessed cardiac tolerance of the concomitant or sequential addition of pertuzumab and trastuzumab to 162 
docetaxel with or without anthracycline in neoadjuvant treatment [54]. The results did not show an 163 
increased incidence of cardiac dysfunction. However, more data is needed to confirm the results of this 164 
study. 165 
A recent literature review concluded that the cardiac impact of these novel drugs was lower than that 166 
of trastuzumab, and they mainly led to an asymptomatic decrease of the LVEF [55]. The mechanisms 167 
responsible for the lower cardiotoxicity of these novel drugs are still not completely understood. 168 
However, lapatinib is known to activate the adenosine monophosphate kinase (AMPK) pathway, 169 
which could protect heart cells against tumor necrosis factor alpha (TNF-α)-induced cell death by 170 
inhibiting its stimulation [45].  171 
 172 
II. PHYSICAL ACTIVITY TO PREVENT TREATMENT-RELATED CARDIOTOXICITY IN 173 
BREAST CANCER 174 
1. Benefits of being physically active for breast cancer patients  175 
The amount of moderate-to-vigorous physical activity is inversely associated with cardiovascular 176 
mortality, and the incidence of cardiovascular disease, stroke and heart failure [16]. Physical activity is 177 
also a cornerstone in cardiometabolic chronic diseases such as diabetes or high blood pressure. Among 178 
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healthy subjects, regular physical activity reduces the incidence of cardiac events such as hypertension 179 
or coronary heart disease [1]. In addition, among breast cancer patients, physical activity can to some 180 
extent improve cardiopulmonary function (increased LVEF, improved heart rate and systolic blood 181 
pressure, etc.) [56–66], suggesting that physical activity could prevent some of the potential negative 182 
effects of treatment-related cardiotoxicity in HER2+ breast cancer subtypes.  183 
A recent literature review highlighted the interest in implementing an exercise intervention program in 184 
the population at risk for cardiotoxicity [67], as is the case with HER2+ breast cancer patients, 185 
especially because breast cancer patients can also have pre-existing comorbidities, such as diabetes 186 
and hypertension, that predispose them to cardiotoxicity [67,68]. The mechanisms explaining the 187 
benefit of physical activity on cardiovascular function are still not clearly known. A preclinical study 188 
conducted on a murine model  showed that physical exercising for 5 consecutive days protected the 189 
cardiomyocyte mitochondria from the oxidative damage and dysfunction induced by doxorubicin [69]. 190 
Indeed, the authors found that in physical exercising conditions, there was a reduction in doxorubicin-191 
induced ROS release from the cardiac mitochondria. In addition, aerobic training induced endogenous 192 
antioxidant mechanisms that protect the heart against ROS [70]. A study conducted on 2973 non-193 
metastatic breast cancer patients assessed the relationship between exposure to physical exercise and 194 
cardiovascular events [71]. The results, with a median follow-up of 8.6 years, showed a reduction of 195 
23 % in the risk of cardiovascular events for patients that followed physical activity recommendations 196 
(i.e. ≥ 9 MET-h/week.) after the end of their treatment (≥ 9 MET-h/week) compared to those who did 197 
not follow the recommendations.  198 
 199 
2. Physical activity interventions improving cardiopulmonary capacities 200 
Haykowsky et al. were the first to specifically study the impact of physical activity on trastuzumab-201 
induced cardiotoxicity. They conducted a trial on 17 HER2+ breast cancer patients. A supervised 202 
physical activity intervention took place in the course of the first 4 months of trastuzumab 203 
administration. The intervention was composed of 3 aerobic sessions of 30 to 60 minutes per week on 204 
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an electrically braked cycle ergometer at 60 to 90% of the oxygen peak consumption (VO2peak). The 205 
results of the trial concluded that although the aerobic activity took place during the chemotherapy, 206 
trastuzumab induced left ventricular cavity dilation and a significant decrease in the ventricular 207 
ejection fraction [72]. Nevertheless, according to the authors, the relatively low program adherence 208 
(59 %) could explain the absence of a cardioprotective effect of physical activity. Indeed, they 209 
highlighted the fact that exercise adherence was predictive of change in peak oxygen consumption and 210 
that patients need to attend ≥ 55 % of the prescribed sessions to derive any benefit on cardiopulmonary 211 
function. Other studies assessed the effect of physical activity interventions during treatment on the 212 
cardiovascular system and cardiorespiratory function among non-HER2+ breast cancer patients (Table 213 
1). The studies were conducted at different moments in treatment: during adjuvant chemotherapy 214 
[73,74],  during other adjuvant treatments [65–70], or after the end of breast cancer treatment [59]. 215 
Rates of adherence to the program were higher than in Haykowsky’s study, ranging from 66 % to 98.4 216 
%, and an improvement in cardiopulmonary function was rapidly observed after the physical activity 217 
program was started. For example, after 8 or 12 weeks of an aerobic exercise intervention, an increase 218 
in the VO2peak and a decrease in systolic blood pressure were observed [63,66]. Furthermore, patients 219 
following a 12-week aerobic intervention enhanced their VO2max by 2.6 ± 3.5 mL/min/kg [60] and 220 
there was an increase of 2.37 ± 0.68 mL/min/kg for those who attended 27 weeks of an aerobic and 221 
reinforcement program [58]. Overall, randomized controlled clinical trials have shown that patients 222 
taking part in a physical activity program have better cardiopulmonary outcomes than those who do 223 
not take part [57–60]. Phase II of Hornsby’s randomized study was the only one conducted on HER2+ 224 
patients treated with neoadjuvant chemotherapy (+ aerobic training) [60]. The intervention consisted 225 
in a one-to-one supervised cycle ergometry session (3 sessions/week) covering the 12 weeks of 226 
neoadjuvant chemotherapy, with progressive intensification of both duration and intensity of the 227 
exercise. There was no resistance training offered in this trial. However, cardiopulmonary function 228 
improved in the intervention group, unlike the control group, in which it decreased. According to De 229 
Luca, a supervised program (24 weeks, 2 sessions of 90 min per week, aerobic and strength training) 230 
at least six months after completion of all cancer therapies, improved VO2max by about 38.8 % from 231 
baseline to the end of the program [59]. One limitation of these studies was the small numbers of 232 
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patients included (N = 20). Studies on larger populations are required. Recently, it has been shown that 233 
a 16-week physical activity intervention for physically inactive overweight or obese breast cancer 234 
patients after treatment improves physical fitness (N = 91) [61]. The authors highlighted the high 235 
adherence rate (96 %) and noted that this could be linked to a reduction in the patients’ barriers to 236 
physical activity. Indeed, patients were free to go to one-to-one supervised exercise sessions every day 237 
of the week from 5 am to 8 pm. Furthermore, parking and bus passes were made available in order to 238 
facilitate access to the facility.  239 
 240 
3. Ongoing interventional clinical trials for HER2+ breast cancer patients 241 
At present, only two French trials, including our own, are studying the effect of an exercise program 242 
on cardiotoxicity among HER2+ patients. CARDAPAC (NCT02433067) is a phase II, prospective, 243 
randomized, multicenter study conducted by a research team in Besançon [76]. It aims to evaluate the 244 
impact on cardiac function of aerobic exercise among HER2+ patients exclusively treated with 245 
trastuzumab. The exercising regime is individualized and consists in 45-minutes of endurance 246 
exercises (of moderate and high intensity), 3 times a week for 3 months. The program starts after the 247 
end of the chemotherapy and radiotherapy if indicated, and patients are monitored for 6 months. The 248 
primary objective of CARDAPAC is to evaluate the incidence rate of cardiotoxicity, defined as a 249 
decrease in the LVEF to less than 50 % or an absolute drop in the LVEF of 10 % from baseline.  250 
Our own study, the APACAN2 (NCT02963363) trial, aims to evaluate the feasibility of home-based 251 
adapted physical activity for HER2+ breast cancer patients treated with neoadjuvant chemotherapy 252 
and anti-HER2 targeted therapy. It is a prospective, non-randomized, interventional study. The 253 
physical activity program takes place precisely during the period of the anthracycline-based 254 
chemotherapy. It comprises both  aerobic and  resistance exercises. The main objective of the study is 255 
to show the feasibility of a physical activity intervention conducted at home, for patients treated with 256 
neoadjuvant chemotherapy and anti-HER2 targeted therapy, in order to comply with the international 257 
recommendations defined by  the WHO (i.e. at least 150 minutes of moderate-intensity aerobic 258 
physical activity or at least 75 minutes of vigorous-intensity activity or an equivalent combination of 259 
moderate-to-vigorous intensity activity throughout the week [3]). There is a lack of data concerning 260 
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physical activity practice from the beginning of breast cancer treatment in case of neoadjuvant 261 
chemotherapy, and this study will allow  the feasibility of home-based adapted physical activity to be 262 
assessed (aerobic and resistance training) for the first time in this early period of treatment. 263 
 264 
According to the data, the need for HER2+ breast cancer patients is to increase or maintain their level 265 
of physical activity until they reach the international recommendations. It also enables their sedentary 266 
time to be reduced in order to offset treatment-induced cardiotoxicity. The intervention for this patient 267 
subgroup needs to be initiated as soon as possible in order to anticipate and prevent any cardiac events. 268 
A cardiopulmonary exercise test enables the intensity of physical activity to be adjusted according to 269 
each patient’s capacities and to ensure that there is no contraindication to exercise. 270 
It is essential to integrate aerobic exercising into the program because of the benefits on the 271 
cardiovascular system. It enables cardiopulmonary function, notably VO2max, to be relatively rapidly 272 
improved among breast cancer patients (Table 1). Nevertheless, muscular strength is also required 273 
because increase in muscle mass is linked to a decrease in fat mass, and thus contributes to better body 274 
composition [73]. Furthermore, De Luca et al. among breast cancer survivors showed that resistance 275 
training limited body mass gain, which is often associated with an increase in fat mass and a loss of 276 
muscle mass [59]. Indeed, adjuvant breast cancer treatments, such as endocrine therapy , are linked to 277 
weight gain mainly corresponding to fat mass gain in the abdominal region [77,78] and physical 278 
activity practice could improve these negative long term side effects. 279 
A particularity of the physical activity program is that it can offer support in many forms to encourage 280 
practice [79–81]. For example, a pedometer can be given to patients to measure the distance  that 281 
needs to be reached  every week. It can even be a pedometer connected to a smartphone application. 282 
Patients could thus see their daily activity and sedentary time, or even monitor their personalized 283 
objectives and their progress. The advantage of this tool is that their sports instructor can also see their 284 
patient’s physical activity and adapt the program according to the patient’s physical fitness. 285 
 286 
III. BARRIERS AND FACILITATORS TO PRACTICE: HOW CANPHYSICAL ACTIVITY PROGRAMS BE 287 
OPTIMISED? 288 
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The success of physical activity interventions lies in the participation of patients.  There is therefore a 289 
real challenge to identify the barriers and facilitators in order to optimize adherence to a physical 290 
activity program. 291 
 292 
1. Barriers to exercising 293 
Possible barriers to practice are numerous and can be physical, psychological or even organisational. It 294 
is essential to identify these barriers so that they can be overcome for the purpose of improving 295 
physical activity practice. Some factors hindering physical activity practice have already been 296 
identified. 297 
Barriers linked to disease or treatment side effects are among the most important. Indeed, Courneya et 298 
al. studied  barriers to physical activity in a three-arm randomized trial (aerobic exercise training 299 
versus resistance exercise training versus usual care) and reported that side effects were the reason for 300 
more than 50 % of missed supervised exercise sessions on offer in their trial during chemotherapy 301 
[82]. Patients mentioned mainly fatigue, nausea, and not feeling well on the day of the chemotherapy 302 
administration as barriers to physical activity, since it interfered with their ability to exercise. 303 
Nevertheless, it should be considered  that before treatment initiation, patients can have comorbidities 304 
that already affect their ability to  engage in physical activity [83]. Further to this, the notion of self-305 
image should also be considered. Changes in appearance and body image are also  barriers to physical 306 
activity because patients can be wearing a wig or a prosthesis [84]. This makes the practice of certain 307 
activities more complicated, such as swimming for example, because of the close-fitting swimsuits 308 
[85]. It adds a further barrier to exercise, especially because of the embarrassment patients might feel 309 
in public. Organisational barriers are the second theme among limitations to physical activity practice. 310 
Firstly, the distance between home or the workplace and the sports facility frequently appears as a 311 
considerable limitation [83,86–88]. What is more, infrastructures are often located in cities, so that 312 
access is more difficult for those who live in the countryside. Nevertheless, even for  patients living in 313 
the city, the risk of encountering traffic problems should also be taken into account as a barrier [86]. 314 
When the disease occurs, patients struggle to maintain a balance between work and family life and 315 
give more value to the time spent with family and/or friends than doing exercise [84]. They want to 316 
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take responsibility for  their families as they did before diagnosis, and this can also be a barrier to 317 
exercise [88,89]. Patients who did not have time to practice any physical activity before, find it all the 318 
more difficult after diagnosis [90,91], especially as a lack of willpower is also a considerable barrier 319 
[82,89–91]. Furthermore, being able to continue to go to work is a real need for certain patients, to 320 
fight emotional distress and to feel that they are in control. However, this requires a lot of energy and 321 
patients are often too tired to engage in a physical activity on top of everything [84]. Furthermore, it 322 
has been shown that socioeconomic status also influences physical activity. Indeed, women with a 323 
higher level of education are more likely to work full time, and alongside to have a lower moderate 324 
exercise level. Thus, employment status could interfere with leisure time and reduce the opportunity to 325 
engage in exercising [92]. 326 
The psychological aspect is another theme highlighted in certain studies [85–87,93,94]. 327 
Overprotection by the patients’ entourage has been recognised as a limitation to physical exercise. 328 
Furthermore, some patients do not know that they can exercise during treatment or are afraid that it 329 
might worsen their symptoms. This raises the problem of the lack of information on physical activity 330 
that should be provided  by the medical staff [93,94]. And although they may feel uncomfortable 331 
exercising in front of healthy people, as mentioned above, patients also report the importance of 332 
support to increase their motivation [89,92–94].  333 
It has been shown that the more barriers there are for  patients, the lower their level of physical activity 334 
[82,95], and also that reducing barriers to exercise is correlated with an increase in physical activity 335 
levels. Indeed, Ottenbacher et al. showed that patients who reduced their barriers from baseline to 1 336 
year increased their physical activity levels by 91 minutes per week [91]. Facilitating access to training 337 
sessions (flexible times, car or bus access, etc.) evidences better adherence rates [61]. 338 
 339 
2. How can patients be encouraged to be physically active during treatment?   340 
Identifying barriers to physical activity provides an understanding of how to encourage patients to be 341 
physically active. First of all, receiving information about the benefits of physical activity during 342 
treatment is highly important [83]. Some studies have shown that patients who are aware of the 343 
benefits of exercise during treatment are more active than those who do not have this information [96]. 344 
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Other studies have shown that the influence of the physician  proves to be the most decisive incentive 345 
among patients to practice a physical activity: by providing reassurance on potential health issues 346 
(restoring confidence in their health, reassurance about fear of injury and fatigue), along with the 347 
physician’s involvement and interest (specific request and monitoring of the patient’s physical 348 
activity) [97,98]. All these elements point to the importance of information to patients and the training 349 
of physicians/oncologists on the effects of physical activity. Finally, a personal background of 350 
physical activity is also important, because it is easier for patients to continue a physical activity 351 
practice during treatment if they were already active before. For other patients, diagnosis appears as a 352 
trigger and a motivational factor that motivates them to take care of themselves [83].  353 
Another key point in promoting physical activity is to personalize the program for each patient. A 354 
randomized controlled study, after a one-year follow-up, showed that patients in the tailored-355 
intervention arm adhered better to the diet and exercise recommendations than the control group who 356 
were only given standardized diet and exercise brochures [99]. This trial underlines the importance of 357 
personalizing the intervention for each patient in order to facilitate enrolment on a training program. It 358 
is also essential to define realistic goals for each patient so as to enhance their feeling of self-efficacy 359 
[100,101], especially since it has been shown that patients who are less inclined to take part in a 360 
physical activity program are also those who feel unable to carry it through [102].  361 
Social support plays a favourable role in physical activity levels. Patients feel comfortable when 362 
exercising with other breast cancer women and developing relationships is a source of motivation 363 
[85,86]. 364 
Lastly, the emergence of mobile applications and connected devices promoting diet and physical 365 
activities has upgraded the classic approach to practice. Using new technologies through applications 366 
for smartphones or other electronic devices has proved to be a motivation for patients [103]. It has 367 
been shown that a physical activity program associated with receiving weekly review emails and 368 
access to an e-counsellor for advice on exercise and physical activity is more efficient than a standard 369 
physical activity program for improving levels of physical activity among  breast cancer patient 370 
survivors [104]. Furthermore, new information and communication technologies appear as a good way 371 
to establish regular patient follow-up, which is paramount during a physical activity program. 372 
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CONCLUSION 373 
As a result of the side effects of the treatment they receive, HER2+ breast cancer patients are 374 
particularly exposed to cardiac events during or after therapy. Over the years, the idea has emerged 375 
that being active during treatment could present several advantages for patients, and studies have 376 
confirmed an improvement in numerous aspects of patient condition during and after treatment 377 
(quality of life, asthenia, treatment compliance, cardiac function, etc.). Trials that have been conducted 378 
on this issue are very heterogeneous and no standard recommendations are available for HER2+ breast 379 
cancer patients. Nevertheless, the importance of practising aerobic exercise is obvious on account of 380 
its benefits for the heart. It is essential to facilitate adherence, in particular, so as to maintain patient 381 
motivation. The practice of physical activity should be viewed as leisure and integrated into the 382 
patient’s daily life. Further studies are certainly required to determine how to integrate physical 383 
activity practice into HER2+ breast cancer patients’ treatment plans. Studies on cost-effectiveness are 384 
also needed to assess the medical- and economic consequence of physical activity practice during 385 
treatment, which could promote a return to professional activity, thereby reducing the long-term costs. 386 
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 708 
FIGURE LEGENDS 709 
Table 1: Physical activity interventions reporting cardiopulmonary outcomes among breast cancer 710 
patients during and after treatment 711 
Adj: Adjuvant; AET: aerobic exercise training; CT: chemotherapy; Ctrl: Control; HRmax: maximum 712 
heart rate; HT: Hormone therapy; NA: Not applicable; NACT: Neoadjuvant chemotherapy; ND: Not 713 
done; RCT: Radiochemotherapy; RET: Resistance exercise training; RM: repetition maximum; RPE: 714 
Rate of perceived exertion; RT: Radiotherapy; UC: usual care; VO2max: maximum peak oxygen 715 
consumption 716 
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STUDY N TREATMENT MODALITY 
PROGRAM 
DURATION 
FREQUENCY ACTIVITY INTENSITY ADHERENCE IMPROVEMENT 
Courneya 
KS, 2007 
82  
Adj CT 
NA NA NA UC NA NA NA 
82 
Group 
(supervised) 
17 weeks  
(±4 
months) 
3 
sessions/week 
RET 
60% to 70% of 
their estimated one 
repetition 
maximum 
68%  
↑ Body strength 
↑ Lean body 
mass 
78 AET 
From 60 to 80% of 
VO2max 
72% 
↑ Aerobic 
fitness 
Fairey 
AS, 2003 
25 
 Intervention 
group) 
Completed 
surgery, RT 
and/or CT 
with or 
without 
current HT 
use 
Group 15 weeks  
3 
sessions/week 
AET 70-75% of VO2max 98.4% Between group 
difference for 
VO2max :  
+ 0.29 L/min 
(p<0.001) 
28  
(Ctrl group) 
No training NA NA NA NA NA 
Cornette 
T, 2016 
22 
(Intervention 
group) NACT or Adj 
CT and RT 
At home 27 weeks 
2 
sessions/week 
1 
session/week 
AET 
RET 
> 3 METs 88% 
 
VO2max : 
+ 1.83 ± 0.68 
ml/min/kg 
 
22 
(Ctrl group) 
NA NA NA UC  NA NA 
VO2max : 
- 1.31 ± 0.65 
mL/min/kg 
24 
 
De Luca 
V, 2016 
10  
(Intervention 
group) 
Surgery + all 
cancer 
therapies 
completed at 
least 6 months 
before 
Group 
(supervised)  
24 weeks 
2 
sessions/week 
AET 
 
 
RET 
 
70% to 80% of 
estimated HRmax 
 
A load of 40% to 
60% of estimated 
1RM  
ND 
↑ Vo2max  
 
+ 38.8 % 
between 
baseline and end 
of intervention 
10  
(Ctrl group) 
NA NA NA NA NA NA 
No significant 
change 
Hornsby, 
2014 
10  
(Intervention 
group) 
NACT 
One-to-one 
supervised 
sessions   
12 weeks 
2 to 3 
sessions/week 
AET 
Moderate to high 
intensity 
66% 
VO2max : 
+ 2.6 ± 3.5 
mL/min/kg 
10  
(Ctrl group) 
NA NA NA NA UC NA NZ 
VO2max :  
- 1.5 ± 2.2 
mL/min/kg 
Travier, 
2015 
102  
(Intervention 
group) 
Adj CT 
Group 18 weeks 
2 
sessions/week 
 
AET 
RET 
Based on the heart 
rate at the 
ventilatory 
threshold as 
determined during 
baseline 
cardiopulmonary 
exercise test 
83% 
VO2max :  
- 0.7 mL/min/kg 
102  
(Ctrl group) 
NA NA NA UC NA NA NA 
Dieli-
Conwright 
CM, 2018 
46 
(Intervention 
group) 
< 6 months 
post-treatment 
(chemo or 
radiotherapy) 
One-to-one 
supervised 
sessions 
16 weeks 
3 
sessions/week 
(2 AET+RET 
and 1 AET) 
AET  
RET 
Moderate-vigorous 
intensity 
96 % 
↑ Vo2max  
↓ Resting heart 
rate 
25 
 
 717 
45 
(Control 
group) 
NA NA NA NA NA NA 
No change in 
physical fitness 
Foucaut 
AM, 2014 
61 Adj RCT Group 3 months 
1 
session/week 
1 
session/week 
AET 
RET 
Moderate to 
vigorous 
80% 
VO2max : 
+ 0;6 ml/min/kg 
Kim CJ, 
2006 
41 Adj therapy Group 8 weeks 
2 
sessions/week 
AET 
RET 
Moderate 78.3% ↑ Vo2peak 
Kolden, 
2012 
40 Adj therapy Group 16 weeks 
3 
sessions/week 
AET 
RET 
Flexibility 
40-60% of 
estimated maximal 
aerobic capacity 
88% 
↑ aerobic 
capacity 
Leach, 
2016 
102  
currently 
treated by CT 
or CT/RT 
discontinued 
within 3 
months 
Group or 
home-based 
exercise  
according 
to patient’s 
preference 
24 weeks 
2 
sessions/week 
1 
session/week 
5-7 
sessions/week 
AET 
RET 
Flexibility 
Mild to vigorous 
80.6%  
(12 week 
assessment) 
 
42%  
(24 week 
assessment) 
VO2max :  
+ 1.9 
mL/min/kg 
Noble, 
2012 
575 
Surgery or CT 
or RT or HT 
Group 12 weeks 
2 
sessions/week 
AET 
RET 
Stretching 
 RPE 11-13 69% 
↓heart rate 
response 
↓ systolic blood 
pressure 
↓ RPE 
